Who Optimizes SG&A Costs Better? Genmab A/S or Ascendis Pharma A/S

Optimizing SG&A Costs: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. Over the past decade, Genmab A/S and Ascendis Pharma A/S have demonstrated contrasting strategies in optimizing these costs. From 2014 to 2023, Genmab A/S consistently reported higher SG&A expenses, peaking at approximately 3.3 billion in 2023, a staggering 41-fold increase from 2014. In contrast, Ascendis Pharma A/S showed a more conservative growth in SG&A expenses, increasing from 6.3 million in 2014 to 264 million in 2023, a 42-fold rise. This data suggests that while both companies have expanded their operations, Genmab A/S has taken a more aggressive approach. Understanding these trends provides valuable insights into their strategic priorities and operational efficiencies, offering a glimpse into the financial dynamics of the biotech industry.